Abstract
Introduction
This real-world, cross-sectional study compared sociodemographic, clinical and treatment characteristics, and patient-reported outcomes (PROs) among racial/ethnic groups in patients with atopic dermatitis (AD) who are candidates for systemic therapy.
Methods
This study included adults with dermatologist- or dermatology practitioner-diagnosed AD enrolled in the CorEvitas AD Registry (July 2020–July 2021). All patients initiated systemic therapy within 12 months prior to or at enrollment or had moderate-to-severe AD (vIGA-AD® ≥ 3 and Eczema Area and Severity Index [EASI] ≥ 12) at enrollment. Patients were categorized into five mutually exclusive racial/ethnic groups: non-Hispanic White, Black, Asian, Other/Multiracial, and Hispanic (any race). Patient, clinical, and treatment characteristics were captured at enrollment. Differences in means or proportions of characteristics among racial/ethnic groups were descriptively summarized using effect sizes. Adjusted prevalence ratios and mean differences were estimated (White race/ethnicity group as the reference category) with 95% confidence intervals (CI).
Results
Among 1288 patients, 64% (n = 822) were White, 13% (n = 167) Black, 10% (n = 129) Asian, 8% (n = 97) Hispanic, and 6% (n = 73) Other/Multiracial. In adjusted analyses, statistically more severe EASI lichenification was noted among Black compared with White patients at the head and neck (mean difference, 0.21, [95% CI 0.06, 0.36]; p = 0.01), trunk (0.32, [0.17, 0.47]; p < 0.001), upper extremities (0.27, [0.09, 0.44]; p = 0.008), and lower extremities (0.39, [0.21, 0.57]; p < 0.001). Statistically more severe EASI lichenification was observed among Asian vs White patients in certain areas (mean difference, head and neck, 0.22 [0.04, 0.39], p = 0.01; trunk, 0.25 [0.07, 0.43], p < 0.001; lower extremities, 0.22 [0.01, 0.43], p < 0.001) and SCORing for AD lichenification (mean difference: 0.34 [0.15, 0.52]; p < 0.001). Significantly higher mean pruritus over the past 7 days for Black (mean difference: 0.63 [0.01, 1.26] and Hispanic patients (0.60 [0.11, 1.09]; p = 0.03) vs White patients was observed. Among AD clinical features, the prevalence of facial erythema was significantly lower among Black compared with White patients (prevalence ratio = 0.38, [0.22, 0.67]; p = 0.007).
Conclusion
Racial/ethnic differences exist in sociodemographic, clinical and treatment characteristics, disease severity, and PROs among real-world AD patients who are candidates for systemic therapy. Recognizing these variations may be of critical importance for dermatologists for the design and delivery of targeted/personalized medicine approaches.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Despite high prevalence of atopic dermatitis (AD) among patients with skin of color in the United States and Canada, the literature on sociodemographic, clinical, and treatment characteristics is limited. |
It is important to characterize differences in sociodemographic, clinical, and treatment characteristics among race/ethnicity groups in real-world AD patients who are candidates for or are currently prescribed systemic therapy. |
What was learned from the study? |
Racial and ethnic differences exist in sociodemographic, clinical and treatment characteristics, disease severity, and patient-reported outcomes among real-world AD patients with AD who are candidates for systemic therapy. |
Racial and ethnic differences should be taken into consideration when treating patients with AD. |
Recognizing these differences may be of critical importance for dermatologists for the design and delivery of targeted/personalized medicine approaches. |
Introduction
Atopic dermatitis (AD), is a chronic, heterogeneous, inflammatory skin disease affecting up to 7% of the US adult population [1,2,3,4,5]. The prevalence of AD has increased over the past few decades [6] and varies within and between countries [7,8,9].
The pathophysiology of AD involves a complex interplay of genetics, immune dysregulation, skin-barrier dysfunction, and environmental factors [7, 8, 10,11,12,13,14,15,16]. AD is a polymorphic disorder, manifesting with erythema, edema, xerosis, erosions/excoriations, oozing and crusting, and lichenification. Pruritus is universal and is the most burdensome symptom of AD for patients and their families [17].
The clinical presentation and severity of AD varies widely among races and ethnicities [18,19,20]. Active AD lesions may present with violaceous or brown tones in patients with skin of color [21]. Patients of East Asian ancestry may present with well-demarcated lesions with prominent scaling and lichenification [19], and sometimes psoriasiform lesions [21]. Black patients may present with papular and perifollicular lesions, lichen planus-like lesions, and may have more extensor involvement [21, 22]. In Black patients, lichenification and prurigo nodularis are observed more than in White patients, potentially because of greater pruritus or difficulty assessing erythema in patients with skin of color [22,23,24].
Assessment and management of AD should include consideration of potential unmet needs in racially diverse patients [25,26,27]. Few studies have examined differences of disease severity and presentation, and patient-reported outcomes (PROs) in diverse patient populations.
This study compared sociodemographic, clinical and treatment characteristics, disease severity, and PROs across racial/ethnic groups in patients with AD who were candidates for and/or were currently prescribed systemic therapy in the United States and Canada, using real-world data from the CorEvitas AD Registry.
Methods
Data Source and Patient Population
The CorEvitas AD Registry is a large, independent, prospective, observational, non-interventional registry for patients with AD diagnosed by a dermatologist or a qualified dermatology practitioner. The registry enrolls adult patients (≥ 18 years) who (a) initiated systemic therapy within 12 months prior to the enrollment visit, (b) were prescribed systemic therapy at the enrollment visit, or (c) were untreated with systemic therapy but had moderate-to-severe AD with Eczema Area Severity Index (EASI) score ≥ 12, and vIGA-AD® ≥ 3 at the enrollment visit. Patients participating in or planning to participate in a double-blind randomized trial for a systemic AD medication were ineligible for registry enrollment. For purposes of determining eligibility, systemic therapy included biologics (dupilumab, ixekizumab, omalizumab, risankizumab, secukinumab, ustekinumab), non-biologics (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, mycophenolic acid, tacrolimus), and small molecules (montelukast sodium, apremilast, baricitinib, tofacitinib, upadacitinib). A few biologics (risankizumab, secukinumab, ustekinumab) and a small molecule (tofacitinib) were included in the list of eligible medications for enrollment in the registry to capture any potential off-label use of systemic therapy for AD.
Longitudinal data were collected from both patients and their treating providers during routine clinical encounters using a standardized data collection method. The scope of data collection included but was not limited to patient demographics (including age, sex, race, and ethnicity), medical history (including all prior and current treatments for AD), disease phenotype and duration, smoking status, alcohol use, disease activity and severity, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes.
This cross-sectional study used data collected from the CorEvitas AD Registry during enrollment visits that occurred from July 21, 2020 through July 28, 2021. For the study period, the registry included 53 private and academic clinical sites with 102 clinicians throughout the US and Canada with 1298 enrolled patients with AD.
All patients were required to provide written informed consent prior to participating. All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB; IntegReview, protocol number Corrona-AD-550). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participating.
Measures
Patients were categorized into five groups based on self-reported race/ethnicity: White-non-Hispanic (White), Black-non-Hispanic (Black), Asian-non-Hispanic (Asian), Other/Multiracial-non-Hispanic (Other/Multiracial) and Hispanic-any race (Hispanic).
Patients’ sociodemographic, clinical, and treatment characteristics were assessed at the time of registry enrollment. Primary outcomes included disease severity (measured using vIGA-AD® [28], EASI [29], and SCORing for AD [SCORAD]) [30] and PROs (assessed using the Patient-Oriented Eczema Measure [POEM] [31], peak pruritus-numeric rating scale [NRS] [32], and AD Control Tool [ADCT]) [33]. Detailed descriptions of PRO measures are provided in the Supplementary Table 1.
Secondary outcomes included specific AD clinical features for which descriptive analyses demonstrated small-to-large effect sizes (ES) for differences by race/ethnicity (phi > 0.10), provided that the overall prevalence in the study cohort was > 5%.
Statistics
Sociodemographic, clinical, and treatment characteristics were summarized descriptively using frequencies with percentages for categorical variables and means with standard deviations for continuous variables. Differences in means or proportions of characteristics among race/ethnicity groupings were descriptively summarized using ES: categorical (phi: 0.10, 0.30, and 0.50 for small, moderate, and large differences, respectively) [34] and continuous (Cohen’s f: small, moderate, and large for values of 0.10, 0.25, and 0.40, respectively) measures [35]. Adjusted prevalence ratios (dichotomous outcomes) and mean differences (continuous/ordinal outcomes) were estimated with 95% confidence intervals (CI) using multivariable mixed effects Poisson and linear regression models, respectively. These adjusted estimates were reported using the White race/ethnicity group as the reference category. Separate models were fitted for each outcome and were adjusted for prespecified covariates (age, sex, geographic region, age of AD symptom onset, prior medications [systemic therapy, systemic corticosteroids, phototherapy, super-potent topical steroids], history of asthma, history of allergic rhinitis, history of eosinophilic esophagitis, history of food allergies), as well as any covariate with at least a moderate difference observed in any race/ethnicity group versus White patients. Statistical significance was defined as p < 0.05; no adjustments were made for multiple comparisons. All statistical analyses were conducted using Stata Release 16 (StataCorp LLC, College Station, TX, USA).
Results
Sociodemographic Characteristics
Overall, 1288 (99%) patients provided information on race and ethnicity, including 167 (13%) Black, 129 (10%) Asian, 97 (8%) Hispanic, 73 (6%) Other, and 822 (64%) White patients. Mean ± SD age in years at enrollment ranged from 38.6 ± 16.4 (Asians) to 52.9 ± 17.7 (Whites, ES = 0.31). Most patients across all racial/ethnic groups were female (range: 59–67%, ES = 0.06). Most of the patients across all racial/ethnic groups reported adult-onset AD. Adult-onset AD was reported more commonly in White patients (70%) than Black (57%), Asian (44%), Other/Multiracial (52%), and Hispanic patients (56%; ES = 0.21; Table 1).
A moderate difference was observed both in work status (ES = 0.30) and geographic region (ES = 0.45) across all racial/ethnic groups. Black patients (51%, 16%) were more likely to work full-time or be disabled than White (45%, 10%), Asian (45%, 2%), Other/Multiracial (42%, 10%), or Hispanic (47%, 5%) patients. White patients were most often from the Midwest (44%), whereas Black patients were most often from the South (51%) and Asian, Other/Multiracial, and Hispanic/Latino patients were most often from the West (43%, 33%, and 43%, respectively). Small ES differences were noted for health insurance type: private/commercial health insurance (range: 52% Other/Multiracial to 70% White; ES = 0.11), Medicare (range: 6% Hispanic to 25% White, ES = 0.19), and Medicaid (range: 10% White to 34% Black, ES = 0.24; Table 1).
Clinical Characteristics
AD lesion locations that varied at enrollment with a small ES (0.12–0.15) included palmar hands (20% Hispanic to 39% White), plantar feet (12% Asian to 25% White), face (42% Black to 62% Asian) and neck (40% White to 63% Asian). Other lesion locations did not meet criteria for ES differences (Table 2).
Clinical features with overall prevalence > 5% and small differences (ES: 0.10–0.19) observed by race/ethnicity included perifollicular accentuation (6% White to 17% Black), prominent head-neck involvement (19% White to 35% Asian), flexural lichenification (range: 21% for White and 33% for Black), facial erythema (6% Black to 28% Asian), allergic shiners (6% White to 21% Other/Multiracial), and Dennie–Morgan fold (7% Black to 21% Other/Multiracial; Table 2).
Disease Severity and Patient-Reported Measures
No statistically significant differences were observed at enrollment by race/ethnicity in vIGA-AD, EASI, or SCORAD. Adjusted analysis of disease severity measures at enrollment identified more severe EASI lichenification in Black patients vs White patients (mean difference, head and neck, 0.21, 95% CI [0.06, 0.36], p = 0.01; trunk, 0.32 [0.17, 0.47], p < 0.001; upper extremities, 0.27 [0.09, 0.44], p = 0.008; lower extremities, 0.39 [0.21, 0.57], p < 0.001) (Fig. 1A, Supplementary Table 2). In adjusted analysis, more severe findings were also noted in Black vs White patients for SCORAD lichenification (mean difference 0.31 [0.15, 0.47], p < 0.001) and SCORAD dryness (0.27 [0.11, 0.43], p = 0.01; Fig. 1B). Adjusted mean difference EASI erythema scores for Black patients vs White patients were: head and neck, − 0.02 (− 0.20, 0.15); trunk, 0.01 (− 0.17, 0.18); upper extremities, − 0.05 (− 0.22, 0.12); and lower extremities, 0.07 (− 0.11, 0.26).
Statistically more severe EASI lichenification was observed in certain areas among Asian vs White patients (adjusted mean difference head and neck, 0.22 [0.04, 0.39], p = 0.01; trunk, 0.25 [0.07, 0.43], p < 0.001; lower extremities, 0.22 [0.01, 0.43], p < 0.001 and SCORAD lichenification (adjusted mean difference 0.34 [0.15, 0.52], p < 0.001) (Fig. 1A, B, Supplementary Table 2). Although not significant, adjusted mean difference EASI erythema score for Asian vs White patients were: head and neck, 0.14 (− 0.06, 0.35); trunk, 0.11 (− 0.10, 0.32); upper extremities, − 0.08 (− 0.28, 0.12); lower extremities, 0.04 (− 0.18, 0.25). The adjusted analysis also identified significantly higher mean pruritus over the past 7 days for Black (mean difference 0.60 [0.11, 1.09], and Hispanic patients (0.63 [0.01, 1.26], p = 0.03) vs White patients (Fig. 1C, Supplementary Table 2). No statistically significant adjusted mean differences were identified for POEM, worst pruritus in past 24 h, or ADCT.
When clinical features at enrollment were examined by multivariable analysis, the prevalence of facial erythema was statistically lower among Black patients vs White patients (prevalence ratio = 0.38 [0.22, 0.67]; p = 0.007), and prevalence of allergic shiners was higher among Black (2.65 [1.72, 4.07]), Asian (1.93 [1.34, 2.80]), and Other/Multiracial (1.88 [1.22, 2.89]) patients vs White patients (p < 0.001; Fig. 1D, Supplementary Table 2). Other observed clinical features did not reach statistical significance.
When EASI severity of signs was dichotomized into moderate/severe vs none/mild, Asian patients had a higher prevalence of moderate/severe edema/papulation in all areas (head and neck prevalence ratio, 1.42 [1.10, 1.84]; trunk, 1.54 [1.17, 2.01]; upper extremities, 1.21 [1.01, 1.46]; lower extremities, 1.35 [1.07, 1.72]) compared with White patients. Although not all differences were statistically significant, Asian patients had a higher prevalence of moderate/severe EASI lichenification in all areas, (head and neck 1.30 [0.91, 1.87]; trunk 1.55 [1.15, 2.11]; upper extremities 1.35 [1.06, 1.72]; lower extremities 1.21 [0.92, 1.58]). In addition, Asian patients had a higher prevalence of moderate/severe SCORAD swelling (1.39 [1.14, 1.69]) and lichenification (1.53 [1.24, 1.90]) versus White patients; Supplementary Table 3).
Compared with White patients, Black patients had a higher prevalence of moderate/severe EASI lichenification in all areas, although not all differences were statistically significant (head and neck, 1.47 [1.02, 2.13]; trunk, 1.50 [1.21, 1.86]; upper extremities, 1.24 [0.98, 1.55]; lower extremities, 1.50 [1.19, 1.90]). Black patients also had a higher prevalence of EASI edema in the lower extremities (1.27 [1.04, 1.55]), and a higher prevalence of moderate/severe SCORAD lichenification (1.32 [1.06, 1.64]; Supplementary Table 3).
In unadjusted analysis, no statistically significant differences were observed by race/ethnicity among disease severity and PRO measures (vIGA-AD, EASI, SCORAD, POEM, and ADCT; Supplementary Table 4).
Treatment Characteristics
Pre-enrollment history of systemic therapy ranged from 40% to 50% among all racial/ethnic groups (ES = 0.04); history of systemic corticosteroids and phototherapy were slightly higher among Asian (37%, 20%) and Other/Multiracial (42%, 15%) patients, in comparison to White (18%, 10%), Black (23%, 7%), and Hispanic (20%, 7%) patients (systemic corticosteroids ES = 0.19; phototherapy ES = 0.12; Fig. 2A). The proportion of patients currently taking systemic therapy ranged from 76% to 92% among all racial/ethnic groups (ES = 0.12). Current use of topical calcineurin inhibitors and crisaborole was slightly higher among Asian (36%, 16%) patients in comparison to other racial/ethnic groups (range 15–25%, 4–7%; ES = 0.15 for both; Fig. 2B).
Discussion
Among real-world AD patients who are candidates for systemic therapy, we observed differences in age of AD symptom onset, work and health insurance status, geographic region, lesion location, treatment characteristics and clinical features across racial and ethnic groups. In adjusted analyses, differences were noted for EASI lichenification, SCORAD lichenification and dryness, average pruritus over the past 7 days, and the clinical features facial erythema and allergic shiners. Previous studies showed differences in prevalence, disease severity, and persistence of AD across different racial/ethnic groups in the US [22, 36]. The present study contributes to the body of literature describing self-reported race/ethnicity in patients with AD.
In this study, a quarter to a third of Asian and Other/Multiracial patients had early-onset AD, whereas almost three quarters of White patients experienced adult-onset AD. In addition, every race/ethnicity group had a higher percentage of patients with adult-onset AD compared with early-onset and childhood-onset AD. While it is surprising that a high number of patients reported adult-onset disease, a meta-analysis recently showed that the pooled proportion of adult-onset AD was 26.1% (CI 16.5–37.2%) [37]. The large percentage of late-onset AD patients in this study could also be explained by the fact that only adults were included in this study, as well as by recall bias — adult patients may not remember having had AD as an infant or child [38].
A moderate difference was identified based on participant work status, with the majority of participants employed full or part time. Notable differences included a larger percentage of students in the Asian population, a smaller percentage of disabled participants in the Asian population, and a higher percentage of retired participants in the White population. While it is difficult to specifically ascertain the consequences of differences in work status in this study, it is known that some occupations are higher risk for worsening of disease in individuals with AD [39]. Therefore, differences in occupations observed between racial/ethnic groups may be due to differences in severity of AD.
White patients were most often from the Midwest, whereas Black patients were most often from the South, and Asian, Other/Multiracial, and Hispanic/Latino patients were most often from the West. In a cross-sectional study using the Medical Expenditure Panel Survey, significant regional differences in race (p < 0.001) and ethnicity (p < 0.001) were observed where most Black patients were from South; however, most non-Hispanic patients were from the Midwest [40].
The proportion of Black patients insured by Medicaid was larger than other race/ethnicity groups. In addition, Hispanic and White patients had the highest percentage of private/commercial health insurance and White patients had the highest percentage of Medicare health insurance. It was shown that public health insurance, such as Medicaid or Medicare, is associated with poorer quality of life measures in AD [41]. Additionally, a study in Black patients reported that those with AD were more likely to use Medicaid insurance and that Medicaid insurance was one of the predictors of harmful financial impact due to out-of-pocket expenses [42].
Small differences were observed in the AD lesion locations at enrollment in palmar hands, plantar feet, face, and neck among race/ethnicity groups. In a study involving a Korean population, the head and neck was the most affected area of the body, followed by the upper extremities, lower extremities, and trunk [43]. In a cross-sectional, population-based study in US adults, lesions on the trunk were significantly more common in Blacks and Hispanics [44].
For clinical features examined in multivariable analysis, only two were identified as statistically significant: facial erythema and allergic shiners. Prevalence of facial erythema was statistically lower among Black patients vs White. It was reported that erythema in darker skin is more likely to be missed [22, 45], and Black patients have up to 6 times the risk of severe AD than White patients after adjusting for their erythema scores [22]. In addition, the use of common scoring systems that rely on skin erythema, including SCORAD and EASI, may underestimate the severity of AD in darker skin types; however, overall disease severity as measured by EASI, SCORAD, and v-IGA were not statistically different between groups [20, 46]. It is possible that measuring erythema may be more challenging in certain body regions. Prevalence of allergic shiners was higher among Blacks, Asians, and Other/Multiracial patients in the current study; this was previously reported in a few studies as a classic presentation of AD in African-American and Nigerian patients [20, 47]. Significant differences between race/ethnicity groups were not noted for the other clinical features analyzed in this study.
More severe EASI and SCORAD lichenification were observed in Black patients vs White patients. This is in congruence with previous studies in which African-American [20] and Nigerian patients [47] were more likely to develop lichenification than White patients. Severe SCORAD dryness was also observed in Black vs White patients. This could be hypothesized to be due to the findings that fewer filaggrin (FLG) gene repeats may lead to drier skin [48] and African-American patients with moderate-to-severe AD have low FLG monomer repeats [49]. Average pruritus over the last 7 days was also more significant in Black and Hispanic patients. Xerosis can certainly contribute to pruritus, but the literature also supports an increased risk of pruritus in Black individuals due to increased trans-epidermal water loss, increased size of mast cell granules, decreased ceramide levels and lower stratum corneum pH [50, 51].
There appear to be fewer data on Hispanic individuals and pruritus in the setting of AD in the literature; this may be an important unmet need to be addressed in future studies. In the current study, statistically more severe EASI lichenification (head and neck, trunk, lower extremities) and SCORAD lichenification were identified among Asian versus White patients. Previous studies showed that compared with Whites, Asians tend to have increased scaling and lichenification [18, 19].
Compared with White patients, Asian patients with moderate/severe vs none/mild signs of AD had a higher prevalence of moderate/severe EASI edema and lichenification in all areas and a higher prevalence of moderate/severe SCORAD swelling and lichenification. In patients with moderate/severe vs none/mild signs of AD, compared with White patients, Asian patients had a higher prevalence of moderate/severe EASI edema and lichenification in all areas and a higher prevalence of moderate/severe SCORAD swelling and lichenification. Black patients also had a higher prevalence of moderate/severe EASI lichenification in all areas, moderate/severe EASI edema in the lower extremities, and moderate/severe SCORAD lichenification compared with White patients.
This study did not identify race/ethnicity differences with regard to past history of systemic therapy for AD, but there was a small effect size for prior treatment with specifically systemic corticosteroids and phototherapy, with Asian and Other/Multiracial more likely to have used these. There was a small effect size difference for taking systemic therapy at study enrollment, with a greater proportion of Black, White, and Other/Multiracial patients taking systemic therapy at enrollment. There are limited studies on efficacy of AD treatments by race, ethnicity and/or skin type [27]; this is an area that requires further research.
This study was designed to assess the association of race/ethnicity with AD disease severity measures and PRO measures. These associations could be due to clinical, epidemiologic, and genetic differences among various race/ethnicity groups and may have clinical implications [48,49,50,51]. Currently, guidelines recommend a similar treatment approach across ethnic groups with subtle differences in skin phototype, genetics, and cultural practices [22]. However, as AD is a heterogeneous disease, it cannot be treated with one-size-fits-all approach. It is crucial to understand how these differences in phenotypes may affect therapeutic responses and influence selection of therapies. Clinical trials involved in the development of novel therapies should include diverse ethnic groups and subset analyses by race/ethnicity. Future studies should focus on assessing the underlying explanation for these observed associations.
Strengths and Limitations
The strength of this study lies with the large number of patients with AD deployed from the registry. This real-world study extensively assessed for phenotyping and patient-reported outcomes in a large dataset from diverse patient populations.
The CorEvitas AD Registry includes a sample of adults with AD that are not necessarily representative of all adults with AD in the US and Canada. The small numbers of patients who self-identify as American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or as Multiracial did not allow for analysis of these individual race/ethnicity categories, due to limitations in estimation and statistical power. These patients were combined into a single group labeled “Other/Multiracial” for all analyses; thus, we were unable to make any inferences regarding these specific race/ethnicity groups. In the adjusted analysis, estimates were reported using the White race/ethnicity group as the reference category. We did not directly compare the disease severity and patient-reported measures between Blacks and Asians; however, we have compared Blacks and Asians with Whites. Future studies may compare the disease severity and patient-reported measures between Blacks and Asians.
Conclusion
In this analysis of real-world patients with AD, differences by race/ethnicity were observed in sociodemographic, clinical and treatment characteristics, disease severity, and PROs. Racial/ethnic differences were observed in EASI head and neck, upper and lower extremities lichenification, SCORAD lichenification and dryness, pruritus, and facial erythema and allergic shiners, even after accounting for potential confounders. Recognizing these variations may be of critical import for dermatologists for the design and delivery of targeted/personalized medicine approaches.
References
Mei-Yen Yong A, Tay YK. Atopic dermatitis: racial and ethnic differences. Dermatol Clin. 2017;35(3):395–402.
Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Investig Dermatol. 2019;139(3):583–90.
Hadi HA, Tarmizi AI, Khalid KA, Gajdács M, Aslam A, Jamshed S. The epidemiology and global burden of atopic dermatitis: a narrative review. Life (Basel). 2021;11(9):936.
Harrop J, Chinn S, Verlato G, Olivieri M, Norbäck D, Wjst M, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37(4):526–35.
Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605.
Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR, International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947-54 e15.
Ait-Khaled N, Odhiambo J, Pearce N, Adjoh KS, Maesano IA, Benhabyles B, et al. Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International Study of Asthma and Allergies in Childhood Phase III. Allergy. 2007;62(3):247–58.
Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, et al. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008;121(1):141-7.e4.
Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, IPTS Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-1258 e23.
Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Investig Dermatol. 2011;131(1):67–73.
Weiland SK, Husing A, Strachan DP, Rzehak P, Pearce N, IPOS Group. Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children. Occup Environ Med. 2004;61(7):609–15.
Thomsen SF, Ulrik CS, Kyvik KO, Hjelmborg J, Skadhauge LR, Steffensen I, et al. Importance of genetic factors in the etiology of atopic dermatitis: a twin study. Allergy Asthma Proc. 2007;28(5):535–9.
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Investig Dermatol. 2009;129(8):1892–908.
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–79.
Ahn K. The role of air pollutants in atopic dermatitis. J Allergy Clin Immunol. 2014;134(5):993–9 (discussion 1000).
Sargen MR, Hoffstad O, Margolis DJ. Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004–2012. J Investig Dermatol. 2014;134(1):51–7.
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51.
Leung DY. Atopic dermatitis: age and race do matter! J Allergy Clin Immunol. 2015;136(5):1265–7.
Noda S, Suarez-Farinas M, Ungar B, Kim SJ, de Guzman SC, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–64.
Vachiramon V, Tey HL, Thompson AE, Yosipovitch G. Atopic dermatitis in African American children: addressing unmet needs of a common disease. Pediatr Dermatol. 2012;29(4):395–402.
McKenzie S, Brown-Korsah JB, Syder NC, Omar D, Taylor SC, Elbuluk N. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261–70.
Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–57.
Oh CC, Li H, Lee W, Tey HL. Biopsychosocial factors associated with prurigo nodularis in endogenous eczema. Indian J Dermatol. 2015;60(5):525.
Shaw FM, Luk KMH, Chen KH, Wrenn G, Chen SC. Racial disparities in the impact of chronic pruritus: a cross-sectional study on quality of life and resource utilization in United States veterans. J Am Acad Dermatol. 2017;77(1):63–9.
Hirano SA, Murray SB, Harvey VM. Reporting, representation, and subgroup analysis of race and ethnicity in published clinical trials of atopic dermatitis in the United States between 2000 and 2009. Pediatr Dermatol. 2012;29(6):749–55.
Charrow A, Xia FD, Joyce C, Mostaghimi A. Diversity in dermatology clinical trials: a systematic review. JAMA Dermatol. 2017;153(2):193–8.
Bhattacharya T, Silverberg JI. Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States. JAMA Dermatol. 2014;150(11):1232–4.
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–46.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–8.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–9.
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15.
Durlak JA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol. 2009;34(9):917–28.
Selya AS, Rose JS, Dierker LC, Hedeker D, Mermelstein RJ. A Practical guide to calculating Cohen’s f(2), a measure of local effect size, from PROC MIXED. Front Psychol. 2012;3:111.
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–8.
Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526-32.e7.
Naleway AL, Belongia EA, Greenlee RT, Kieke BA Jr, Chen RT, Shay DK. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med. 2003;139(1):1–7.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema—part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–26.
Wu KK, Nguyen KB, Sandhu JK, Armstrong AW. Does location matter? Geographic variations in healthcare resource use for atopic dermatitis in the United States. J Dermatolog Treat. 2021;32(3):314–20.
Schwartzman G, Lei D, Ahmed A, Chavda R, Gabriel S, Silverberg JI. Longitudinal course and phenotypes of health-related quality of life in adults with atopic dermatitis. Clin Exp Dermatol. 2022;47(2):359–72.
Chovatiya R, Begolka WS, Thibau IJ, Silverberg JI. Financial burden and impact of atopic dermatitis out-of-pocket healthcare expenses among black individuals in the United States. Arch Dermatol Res. 2022;314:739–47.
Chu H, Shin JU, Park CO, Lee H, Lee J, Lee KH. Clinical diversity of atopic dermatitis: a review of 5,000 patients at a single institute. Allergy Asthma Immunol Res. 2017;9(2):158–68.
Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341–8.
Sangha AM. Dermatological conditions in SKIN OF COLOR: managing atopic dermatitis. J Clin Aesthet Dermatol. 2021;14(3 Suppl 1):S20–2.
Ben-Gashir MA, Hay RJ. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol. 2002;147(5):920–5.
Nnoruka EN. Current epidemiology of atopic dermatitis in south-eastern Nigeria. Int J Dermatol. 2004;43(10):739–44.
Ginger RS, Blachford S, Rowland J, Rowson M, Harding CR. Filaggrin repeat number polymorphism is associated with a dry skin phenotype. Arch Dermatol Res. 2005;297(6):235–41.
Quiggle AM, Goodwin ZA, Marfatia TR, Kumar MG, Ciliberto H, Bayliss SJ, et al. Low filaggrin monomer repeats in African American pediatric patients with moderate to severe atopic dermatitis. JAMA Dermatol. 2015;151(5):557–9.
Ingrasci G, El-Kashlan N, Alexis A, Yosipovitch G. Chronic itch in African Americans: an unmet need. Arch Dermatol Res. 2022;314(5):405–15.
McColl M, Boozalis E, Aguh C, Eseonu AC, Okoye GA, Kwatra SG. Pruritus in black skin: unique molecular characteristics and clinical features. J Natl Med Assoc. 2021;113(1):30–8.
Acknowledgements
Funding
This study was sponsored by CorEvitas, LLC and the analysis was funded by Eli Lilly and Company. Access to study data was limited to CorEvitas, and CorEvitas statisticians completed all the analysis; all authors contributed to the interpretation of the results. CorEvitas has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Inc., LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and UCB S.A.
Medical Writing, Editorial, and Other Assistance
The authors would like to thank all the investigators, the clinical staff, and patients who participate in the CorEvitas AD Registry. Amit Kumar Koushik and Suchita Dubey, employees of Eli Lilly Services India Private Limited, provided medical writing support.
Author Contributions
Conceptualization: Jonathan I. Silverberg, Vivian Y. Shi, Robert R. McLean. Formal Analysis: Angel Cronin. Funding Acquisition: Evangeline Pierce. Investigation: Jonathan I. Silverberg, Vivian Y. Shi, Robert R. McLean. Methodology: Jonathan I. Silverberg, Vivian Y. Shi, Angel Cronin, Robert R. McLean. Writing—Original: Maria Jose Rueda, Amber R. Atwater, Evangeline Pierce. Draft Preparation: Maria Jose Rueda, Amber R. Atwater, Evangeline Pierce. Writing—Review and Editing: Angel Cronin, Robert R. McLean, Maria Jose Rueda, Amber R. Atwater, and Evangeline Pierce.
Disclosures
Jonathan I. Silverberg: received honoraria as a consultant and/or advisory board member for Abbvie, AObiome, Arcutis, Alamar, Amgen, Arena, Arcutis, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, and Union; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; institution received grants from Galderma, and Pfizer. Vivian Y. Shi: on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Alumis Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin and Skin Actives Scientific. Andrew Alexis: Grants (funds to institution): Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Vyne, Galderma, Valeant (Bausch Health), Cara, Arcutis, Dermavant, Abbvie, and Castle; advisory board/consulting: Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L’Oreal, BMS, Bausch health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, and Incyte; speaker: Regeneron, SANOFI-Genzyme, Pfizer, and BMS. Evangeline Pierce: employee of Eli Lilly and Company. Angel Cronin: employee of CorEvitas, LLC. Robert R. McLean: employee of CorEvitas, LLC. Carla Roberts-Toler: employee of CorEvitas, LLC. Maria Jose Rueda: employee of Eli Lilly and Company. Amber R. Atwater: employee of Eli Lilly and Company; prior consultation with Henkel; previous recipient of Pfizer Independent Grant for Learning and Change. Eric Simpson: personal fees from Advances in Cosmetic Medical Derm Hawaii LLC, AbbVie, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Boehringer Ingelheim USA, Inc., Boston Consulting Group, Bristol Myers Squibb — BMS, Collective Acumen LLC (CA), CorEvitas, Dermira, Eli Lilly, Evelo Biosciences, Evidera, ExcerptaMedica, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Incyte, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, Leo Pharm, Medscape LLC, Merck, MauiDerm, MLG Operating, MJH holding, Pfizer, Physicians World LLC, PRImE, Regeneron, Revolutionizing Atopic Dermatitis Inc, Roivant, Sanofi-Genzyme, Trevi therapeutics, Valeant, Vindico Medical education, and WebMD; grants (or serves as Principal investigator role) from AbbVie, Acrotech Biopharma Inc, Amgen, Arcutis, Aslan, Castle Biosciences, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, and Target RWE. These potential conflicts of interest have been reviewed and managed by OHSU.
Compliance with Ethics Guidelines
All patients were required to provide written informed consent prior to participating. All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central IRB (IntegReview, protocol number Corrona-AD-550). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participating.
Data Availability
Data are available from CorEvitas, LLC through a commercial subscription agreement and are not publicly available. No additional data are available from the authors.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Silverberg, J.I., Shi, V.Y., Alexis, A. et al. Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry. Dermatol Ther (Heidelb) 13, 2045–2061 (2023). https://doi.org/10.1007/s13555-023-00980-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-023-00980-6